Literature DB >> 27425192

Changes of the Sensory Abnormalities and Cortical Excitability in Patients with Complex Regional Pain Syndrome of the Upper Extremity After 6 Months of Multimodal Treatment.

Elena K Enax-Krumova1, Melanie Lenz1, Jule Frettlöh1, Oliver Höffken1, Annika Reinersmann2, Andreas Schwarzer2, Andrea Westermann2, Martin Tegenthoff1, Christoph Maier2.   

Abstract

Objective: The most prominent sensory sign of the complex regional pain syndrome (CRPS) is blunt hyperalgesia, but longitudinal studies on its relation to the outcome of long-term multimodal treatment are lacking.
Methods: We examined 24 patients with CRPS type I using standardized Quantitative Sensory Testing on the affected hand and the contralateral hand at baseline and 6 months following treatment. Somatosensory evoked potentials after single and paired-pulse stimulation of the median nerve were performed to assess the paired-pulse suppression (n = 19). Treatment response at follow-up was defined as pain relief > 30% and improved hand function. Statistics: Wilcoxon test, Pearson correlation.
Results: At baseline, similar to previous studies, the pressure pain threshold (PPT) was significantly decreased and the pain response to repeated pinprick stimuli was significantly increased, while all detection thresholds were within the normal range without any difference between the later treatment responders and non-responders. After 6 months of treatment, the PPT increased significantly in the whole study group. However, the pressure hyperalgesia improved only in treatment responders (n = 17, P  < 0.05), whereas there was no improvement in non-responders (n = 7). The rest of the sensory profile remained nearly unchanged. There was a correlation between the paired-pulse suppression and the PPT only at follow-up (r = 0.49, P  < 0.05), but not at baseline, where low pressure pain threshold was associated with impaired paired-pulse suppression.
Conclusion: Thus, the persistence of blunt hyperalgesia seems to be associated with impaired paired-pulse suppression, both representing maladaptive central nervous changes in CRPS, which may account for the treatment non-response in this subgroup.
© 2016 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  Complex Regional Pain Syndrome; Cortical Disinhibition; Pressure Hyperalgesia; Sensory Abnormalities; Treatment Effects

Mesh:

Year:  2017        PMID: 27425192     DOI: 10.1093/pm/pnw147

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  4 in total

1.  Intact tactile anisotropy despite altered hand perception in complex regional pain syndrome: rethinking the role of the primary sensory cortex in tactile and perceptual dysfunction.

Authors:  Annika Reinersmann; Ian W Skinner; Thomas Lücke; Nicola Massy-Westropp; Henrik Rudolf; G Lorimer Moseley; Tasha R Stanton
Journal:  PeerJ       Date:  2021-05-03       Impact factor: 2.984

2.  Manual Therapy Reduces Pain Behavior and Oxidative Stress in a Murine Model of Complex Regional Pain Syndrome Type I.

Authors:  Afonso S I Salgado; Juliana Stramosk; Daniela D Ludtke; Ana C C Kuci; Daiana C Salm; Lisandro A Ceci; Fabricia Petronilho; Drielly Florentino; Lucineia G Danielski; Aline Gassenferth; Luana R Souza; Gislaine T Rezin; Adair R S Santos; Leidiane Mazzardo-Martins; William R Reed; Daniel F Martins
Journal:  Brain Sci       Date:  2019-08-10

3.  Low test-retest reliability of a protocol for assessing somatosensory cortex excitability generated from sensory nerves of the lower back.

Authors:  Katja Ehrenbrusthoff; Cormac G Ryan; Denis J Martin; Volker Milnik; Hubert R Dinse; Christian Grüneberg
Journal:  Front Hum Neurosci       Date:  2022-08-23       Impact factor: 3.473

4.  Low mechano-afferent fibers reduce thermal pain but not pain intensity in CRPS.

Authors:  Heidrun H Krämer; Susann Seddigh; Kathrin Habig; Gothje Lautenschläger; Hagen Maxeiner; Frank Birklein
Journal:  BMC Neurol       Date:  2021-07-09       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.